Reference : Absence de benefice de l'administration intermittente de l'insuline lors d'un traitement...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Absence de benefice de l'administration intermittente de l'insuline lors d'un traitement par pompe a perfusion sous-cutanee chez le diabetique de type-1.
[fr] Lack of benefit from the intermittent administration of insulin in treatment using subcutaneous perfusion pump in type 1 diabetes
Lilet, Henri mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine nucléaire >]
Krzentowski, G. [> > > >]
Bodson, Arthur [> > > >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Lefebvre, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Diabète & Métabolisme
Yes (verified by ORBi)
[en] 3-Hydroxybutyric Acid ; Adult ; Blood Glucose/analysis ; Diabetes Mellitus, Type 1/blood/drug therapy ; Drug Administration Schedule ; Fatty Acids, Nonesterified/blood ; Female ; Glycerol/blood ; Humans ; Hydroxybutyrates/blood ; Insulin/blood ; Insulin Infusion Systems ; Kinetics ; Male
[en] Our study is based on two constatations: 1) Hyperinsulinaemia, a possible atherogenic factor, is frequent under continuous subcutaneous insulin infusion. 2) Pulsatile intravenous insulin delivery improve the insulin's hypoglycaemic activity. To test if equivalent metabolic control can be obtained with a reduced intermittent subcutaneous infused insulin dose, we compared nocturnal metabolic control of 8 c-peptide negative type 1 diabetic patients under three experimental conditions: Continuous usual dose test (1.0 +/- 0.1 u/h); Intermittent half dose test (1.0 +/- 0.1 u/h, 30 min/h); Continuous half dose test (0.5 +/- 0.05 u/h) Five parameters were monitored: blood glucose, plasma free insulin and beta-hydroxy-butyrate, free fatty acid and glycerol plasma level. No significant differences were found between intermittent and continuous half-dose tests. We conclude that, in our experimental conditions, intermittent subcutaneous insulin infusion does not reduce the metabolic degradation induced by insulin dose reduction.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.